Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease.
about
Antibody development against biologic agents used for the treatment of inflammatory bowel disease and antibody prevention with immunosuppressivesAzathioprine or 6-mercaptopurine for maintenance of remission in Crohn's diseaseAzathioprine or 6-mercaptopurine for induction of remission in Crohn's diseasePredicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel diseaseImmunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practiceInfliximab-Related Infusion Reactions: Systematic ReviewOptimizing the use of biological therapy in patients with inflammatory bowel diseaseUse of the tumor necrosis factor-blockers for Crohn's diseaseCurrent therapy of pediatric Crohn's diseaseSystematic review with meta-analysis: infliximab and immunosuppressant therapy vs. infliximab alone for active ulcerative colitisReview article: Infliximab therapy for inflammatory bowel disease--seven years onIncidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview.Treatment of perianal fistula in Crohn's disease: a systematic review and meta-analysis comparing seton drainage and anti-tumour necrosis factor treatment.A multicenter retrospective experience of infliximab in Crohn's disease patients: infusion reaction rates and treatment persistencyMedical management of Crohn's disease: current therapy and recent advances.The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study.Ethical considerations for clinical trials in inflammatory bowel diseaseCystic fibrosis and Crohn's disease: successful treatment and long term remission with infliximab.Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease.Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease.Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study.Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease.Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension.Effectiveness of adalimumab for ambulatory ulcerative colitis patients after failure of infliximab treatment: a first "real-life" experience in primary gastroenterology centers in Italy.Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial.Certolizumab pegol: an evidence-based review of its place in the treatment of Crohn's diseaseInfliximab in the treatment of plaque type psoriasis.Adalimumab serum levels and antidrug antibodies towards adalimumab in peripheral spondyloarthritis: no association with clinical response to treatment or with disease relapse upon treatment discontinuationCurrent Controversies in Crohn's Disease: A Roundtable Discussion of the BRIDGe GroupSignificance of low level infliximab in the absence of anti-infliximab antibodies.Efficacy and safety of adalimumab for the Crohn's disease: a systematic review and meta-analysis of published randomized placebo-controlled trials.Optimizing the use of anti-tumor necrosis factor in the management of patients with Crohn's disease.Biologics in paediatric Crohn's disease.Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.Effectiveness and Safety of Immunomodulators With Anti-Tumor Necrosis Factor Therapy in Crohn's DiseaseEffectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease.Inflammatory bowel disease patients are frequently nonadherent to scheduled induction and maintenance infliximab therapy: A Canadian cohort study.Immunogenicity of biological agents in inflammatory bowel disease.
P2860
Q24185835-5B4D955C-CB56-4235-A910-2439B3A4DEE0Q24186291-A68D9E3C-3B3F-45F8-9FCC-5AC0182B45B1Q24197676-3F974D8C-7850-43A6-A9F9-40D1C79238B6Q26745721-4DCA9E8F-3ABE-4526-B8F6-3FA9EEACD941Q26798357-FE7D251E-8D80-4C10-A9A4-457B77C04FEFQ27013835-0AE559E3-D7DD-4039-BF82-DB3F6FAD8A1BQ27025513-FD3313A9-7294-4157-BF9F-06A043B7FEEEQ27030762-3682AED7-BF40-471D-8A86-90646FE37BB9Q28081919-C3511B13-03EB-4B12-952A-6ADC42D96C36Q28088683-CA03F1E6-9C44-4597-9C37-EA4F2D90F1F9Q28294134-6AC21A3F-74D8-4503-AD55-5F7F0FE3BAFBQ30235581-20B53482-3D66-405A-B53F-A62C656B0A7CQ30251864-36866A18-9620-4F36-9E95-B9DEC4C7FAAFQ30430605-6CDD6DB4-E5E1-47DA-B07D-58CBF0C97B26Q30450875-0334DC05-153C-4C1F-A2AB-169008599733Q30995889-77487B07-542C-4187-BAF2-B274DAD79DEFQ33371653-A1D66F2B-1F2A-4ED9-B5AF-9DB33096D73FQ33561988-16F9AEED-5417-4D6B-A8A0-EE5B619C537DQ33798912-4D4BD3CB-04BD-4EFD-A159-8755E9050722Q33798966-E8F80ED8-191E-4969-9470-8730BB6424B4Q33874790-2A30DAC4-F685-4C78-9E84-A7A761D71DEAQ34100121-52D53426-DAAF-4FAB-B333-94CE37DF7658Q34127277-EDD6889F-E199-429E-AF59-A51D822E7EF3Q34157346-EB48F387-F8FD-48C3-B957-571DD898BE54Q34303155-F80DD048-459E-4DF5-B491-4E0D91D91B49Q34431219-7A5F1574-7E67-4B11-B905-31628783273FQ34449843-3E01C913-9103-4252-BB87-B54F54407A5AQ34620291-8BE8BFDD-465B-435F-AB3E-F03754FC3191Q34669637-9D95D69A-C135-4BA3-BA3A-F958A00A3D78Q35013983-98129908-125D-4193-B5C3-0DAF50578B24Q35069511-6EAB3F25-E1D4-4B0F-AD97-E8EE10CEBC65Q35177220-BD7B6164-2BB0-40A7-8009-E8A941EDD294Q35561386-47E4F1E7-A656-4A9A-9AD3-652FF7256E1FQ35579308-49FC3590-0A77-4182-81C0-15C20288946CQ35579517-0014F076-5273-48AB-ABF5-AAEF70DDFFA6Q35638252-719F1441-B414-4599-8AD0-E0A9D8D4E1D2Q35763489-BB19CB18-7008-471D-8877-23955BF0EE9AQ35954116-8BC8CDBA-FEA6-4047-AC0B-3514B94609B4Q36082156-08A0FF68-5014-4578-9DAE-E617739A84EFQ36113933-369C5DCF-ED96-415B-8051-EC5318CD2CE0
P2860
Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Incidence and importance of an ...... treatment in Crohn's disease.
@en
Incidence and importance of an ...... treatment in Crohn's disease.
@nl
type
label
Incidence and importance of an ...... treatment in Crohn's disease.
@en
Incidence and importance of an ...... treatment in Crohn's disease.
@nl
prefLabel
Incidence and importance of an ...... treatment in Crohn's disease.
@en
Incidence and importance of an ...... treatment in Crohn's disease.
@nl
P2093
P1476
Incidence and importance of an ...... treatment in Crohn's disease.
@en
P2093
Allan Olson
Carrie L Wagner
Lloyd Mayer
Mohan Bala
Robert H Diamond
Stephen B Hanauer
Suzanne Travers
Warren Bao
P304
P356
10.1016/S1542-3565(04)00238-1
P407
P577
2004-07-01T00:00:00Z